GlassScriptPhysician profile
Andrew Whiteley
NPI 1225328743
$1,708,102.63
in general payments reported to CMS, 2019-2025
52 companies · $98K in 2025
The $98K reported for 2025 was more than what 98% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71K · 2020: $63K · 2021: $583K · 2022: $508K · 2023: $241K · 2024: $145K · 2025: $98K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $315K · Consulting Fee: $111K · Travel and Lodging: $46K · Food and Beverage: $10K · Honoraria: $1,380 · Education: $43.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $315,426.25 |
| Consulting Fee | $110,950.13 |
| Travel and Lodging | $45,662.80 |
| Food and Beverage | $10,095.20 |
| Honoraria | $1,380.00 |
| Education | $43.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $1,066,192.33 | 2019-2023 | Adcetris |
| Glaxosmithkline, LLC. | $207,515.14 | 2020-2025 | Ojjaara, Shingrix |
| Beigene USA, INC. | $178,376.79 | 2020-2025 | Brukinsa |
| Beone Medicines USA, INC. | $66,092.64 | 2025 | Brukinsa |
| Jazz Pharmaceuticals INC. | $35,470.30 | 2019-2024 | |
| Pfizer INC. | $27,700.67 | 2019-2025 | |
| Sobi, INC | $18,486.99 | 2021-2025 | |
| Agios Pharmaceuticals, INC. | $18,205.36 | 2019-2021 | |
| Epizyme, INC. | $16,155.10 | 2020-2022 | |
| Janssen Scientific Affairs, LLC | $13,423.97 | 2019-2021 | |
| Abbvie INC. | $9,208.43 | 2019-2024 | Venclexta |
| Incyte Corporation | $7,255.28 | 2021-2024 | Monjuvi, Jakafi |
| Genzyme Corporation | $6,871.02 | 2020-2025 | |
| Cti Biopharma Corp. | $5,128.17 | 2022-2023 | Vonjo |
| Servier Pharmaceuticals LLC | $4,839.79 | 2021-2024 |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $4,069.18 | 2020-2025 | Xpovio |
| Astrazeneca Pharmaceuticals LP | $4,038.24 | 2020-2025 | Calquence |
| Gilead Sciences, INC. | $2,751.91 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $2,126.28 | 2019-2024 | Eliquis |
| Adaptive Biotechnologies Corporation | $2,060.57 | 2020-2024 | Clonoseq |
| Janssen Global Services, LLC | $2,020.00 | 2021 | |
| Dova Pharmaceuticals | $1,818.02 | 2019-2021 | |
| Ipsen Biopharmaceuticals, INC | $1,782.72 | 2023-2024 | Tazverik |
| Novartis Pharmaceuticals Corporation | $1,651.73 | 2021-2025 | |
| Beigene, LTD. | $975.00 | 2020-2021 | |
| Geron Corporation | $960.00 | 2025 | Rytelo |
| Genmab U.S., INC. | $546.71 | 2023-2025 | Epkinly |
| Janssen Biotech, INC. | $463.89 | 2019-2023 | Darzalex, Imbruvica, Tecvayli |
| Astellas Pharma US INC | $319.06 | 2019-2024 | Xospata |
| Rigel Pharmaceuticals, INC. | $227.72 | 2021-2024 | Rezlidhia, Tavalisse |
| Adc Therapeutics America, INC. | $203.24 | 2022-2024 | |
| Kite Pharma, INC. | $150.45 | 2021-2023 | Yescarta |
| Eli Lilly and Company | $132.26 | 2024 | Jaypirca |
| Blueprint Medicines Corporation | $127.43 | 2021-2024 | Ayvakit |
| Alexion Pharmaceuticals, INC. | $122.08 | 2019 | |
| Acrotech Biopharma INC. | $108.09 | 2021-2023 | Beleodaq |
| Takeda Pharmaceuticals U.S.A., INC. | $93.79 | 2019-2024 | Iclusig |
| Secura Bio, INC. | $71.74 | 2021 | |
| Lilly USA, LLC | $60.76 | 2024 | Jaypirca |
| Stemline Therapeutics INC. | $54.24 | 2022 | |
| Celgene Corporation | $48.84 | 2023 | Reblozyl |
| Merck Sharp & Dohme LLC | $41.89 | 2023-2024 | Keytruda |
| Genentech USA, INC. | $26.86 | 2023 | Lunsumio, Polivy, Columvi |
| Pharmacyclics LLC, An Abbvie Company | $26.48 | 2023 | Imbruvica |
| Legend Biotech USA INC. | $25.14 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $24.66 | 2021 | |
| Pharmaessentia USA Corporation | $24.13 | 2023 | Besremi |
| Taiho Oncology, INC. | $14.16 | 2022 | |
| Acceleron Pharma, INC. | $13.38 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Whiteley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.